177 related articles for article (PubMed ID: 37428871)
21. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
22. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
23. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
24. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
25. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Pan D; Kobayashi A; Jiang P; Ferrari de Andrade L; Tay RE; Luoma AM; Tsoucas D; Qiu X; Lim K; Rao P; Long HW; Yuan GC; Doench J; Brown M; Liu XS; Wucherpfennig KW
Science; 2018 Feb; 359(6377):770-775. PubMed ID: 29301958
[TBL] [Abstract][Full Text] [Related]
26. Individual Bromodomains of Polybromo-1 Contribute to Chromatin Association and Tumor Suppression in Clear Cell Renal Carcinoma.
Porter EG; Dykhuizen EC
J Biol Chem; 2017 Feb; 292(7):2601-2610. PubMed ID: 28053089
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
28. [Exploration of novel therapeutic targets in acute myeloid leukemia via genome-wide CRISPR screening].
Yamauchi T
Rinsho Ketsueki; 2019; 60(7):810-817. PubMed ID: 31391371
[TBL] [Abstract][Full Text] [Related]
29. CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis.
Sarrou E; Richmond L; Carmody RJ; Gibson B; Keeshan K
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549410
[TBL] [Abstract][Full Text] [Related]
30. Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression.
Bursch KL; Goetz CJ; Jiao G; Nuñez R; Olp MD; Dhiman A; Khurana M; Zimmermann MT; Urrutia RA; Dykhuizen EC; Smith BC
J Biol Chem; 2024 Apr; 300(4):107146. PubMed ID: 38460939
[TBL] [Abstract][Full Text] [Related]
31. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
32. PLGA-Nanoparticles for Intracellular Delivery of the CRISPR-Complex to Elevate Fetal Globin Expression in Erythroid Cells.
Cruz LJ; van Dijk T; Vepris O; Li TMWY; Schomann T; Baldazzi F; Kurita R; Nakamura Y; Grosveld F; Philipsen S; Eich C
Biomaterials; 2021 Jan; 268():120580. PubMed ID: 33321292
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9 as a tool to dissect cancer mutations.
Sayed S; Paszkowski-Rogacz M; Schmitt LT; Buchholz F
Methods; 2019 Jul; 164-165():36-48. PubMed ID: 31078796
[TBL] [Abstract][Full Text] [Related]
34. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
[TBL] [Abstract][Full Text] [Related]
36. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.
Shi J; Wang E; Milazzo JP; Wang Z; Kinney JB; Vakoc CR
Nat Biotechnol; 2015 Jun; 33(6):661-7. PubMed ID: 25961408
[TBL] [Abstract][Full Text] [Related]
37. Modeling and targeting of erythroleukemia by hematopoietic genome editing.
Iacobucci I; Qu C; Varotto E; Janke LJ; Yang X; Seth A; Shelat A; Friske JD; Fukano R; Yu J; Freeman BB; Kennedy JA; Sperling AS; Zheng R; Wang Y; Jogiraju H; Dickerson KM; Payne-Turner D; Morris SM; Hollis ES; Ghosn N; Haggard GE; Lindsley RC; Ebert BL; Mullighan CG
Blood; 2021 Mar; 137(12):1628-1640. PubMed ID: 33512458
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
39. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis.
Li L; Fan XS; Xia QY; Rao Q; Liu B; Yu B; Shi QL; Lu ZF; Zhou XJ
Hum Pathol; 2014 Nov; 45(11):2247-54. PubMed ID: 25200863
[TBL] [Abstract][Full Text] [Related]
40. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.
Jaiswal AK; Truong H; Tran TM; Lin TL; Casero D; Alberti MO; Rao DS
Sci Rep; 2021 Jun; 11(1):13158. PubMed ID: 34162911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
